PT - JOURNAL ARTICLE AU - Maxim Armstrong AU - Andrew R. Harris AU - Michael V. D’Ambrosio AU - Jean T. Coulibaly AU - Samuel Essien-Baidoo AU - Richard K.D. Ephraim AU - Jason R. Andrews AU - Isaac I. Bogoch AU - Daniel A. Fletcher TI - Point-of-care sample preparation and automated quantitative detection of <em>Schistosoma haematobium</em> using mobile phone microscopy AID - 10.1101/2021.11.03.21265895 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.03.21265895 4099 - http://medrxiv.org/content/early/2021/11/04/2021.11.03.21265895.short 4100 - http://medrxiv.org/content/early/2021/11/04/2021.11.03.21265895.full AB - Schistosoma haematobium continues to pose a significant public health burden despite ongoing global control efforts. One of several barriers to sustained control (and ultimately elimination) is the lack of access to highly sensitive diagnostic or screening tools that are inexpensive, rapid, and can be utilized at the point of sample collection. Here, we report an automated point-of-care diagnostic based on mobile phone microscopy that rapidly images and identifies S. haematobium eggs in urine samples. Parasite eggs are filtered from urine within a specialized, inexpensive cartridge that is then automatically imaged by the mobile phone microscope (the “SchistoScope”). Parasite eggs are captured at a constriction point in the tapered cartridge for easy imaging, and the automated quantification of eggs is obtained upon analysis of the images by an algorithm. We demonstrate S. haematobium egg detection with greater than 90% sensitivity and specificity using this device compared to the field gold standard of conventional filtration and microscopy. With simple sample preparation and image analysis on a mobile phone, the SchistoScope combines the diagnostic performance of conventional microscopy with the analytic performance of an expert technician. This portable device has the potential to provide rapid and quantitative diagnosis of S. haematobium to advance ongoing control efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a generous gift from Mitsuru and Lucinda Igarashi, the Blum Center for Developing Economies at UC Berkeley through a grant from USAID, and donors to the Health Tech CoLab (DAF), as well as funding from an MSH-UHN AMO Innovation Funding grant and Ontario New Frontiers Grant (NFRFE/2020/00922).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University Health Network, Toronto gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in this study is available from the corresponding author upon reasonable request.